Brief: Transcode Therapeutics Reports Positive Preclinical Results With Its Immunotherapy Candidate For Pancreatic Cancer
09/11/2022 12:41
Nov 9 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS REPORTS POSITIVE PRECLINICAL
RESULTS WITH
ITS IMMUNOTHERAPY CANDIDATE, TTX-SIPDL1, IN PANCREATIC
ADENOCARCINOMA
Source text for Eikon: ID:nGNX3r454j
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors